Dilated Cardiomyopathy (DCM) Cell Models for Research

Dilated cardiomyopathy (DCM) is a leading cause of heart failure and the most common indication for heart transplantation. According to the Global Burden of Disease Study 2019, the global prevalence of DCM is estimated at 1 in 2,500 individuals, with an annual incidence of 7 per 100,000. In the United States, DCM accounts for approximately 10,000 deaths annually (CDC, 2021). The 5-year mortality rate ranges from 20% to 50% depending on etiology, with higher mortality in patients with NYHA class III-IV symptoms. Key risk factors include genetic mutations (found in 30-50% of cases), viral myocarditis, alcohol abuse, chemotherapy (e.g., anthracyclines), and pregnancy (peripartum cardiomyopathy).

Sources: WHO Global Health Estimates 2020; NCI SEER Cancer Stat Facts (for cancer therapy-related DCM); American Heart Association 2022 Heart Disease and Stroke Statistics.

DCM is an ideal disease for mechanistic studies due to its genetic heterogeneity and well-characterized molecular pathways. Over 50 genes have been linked to DCM, with titin (TTN), lamin A/C (LMNA), myosin heavy chain 7 (MYH7), and troponin T2 (TNNT2) being the most frequently mutated. Public datasets such as ClinVar, gnomAD, and the DCM Precision Medicine Consortium provide extensive variant information. Open questions include: How do truncating TTN variants cause haploinsufficiency? What role do nuclear envelope proteins play in mechanotransduction? How can gene-edited cell models recapitulate patient-specific phenotypes for drug screening? These questions drive demand for isogenic CRISPR models.

DCM is not a carcinogenic disease, but its pathogenesis involves several key molecular pathways that can be modeled in gene-edited cells:

1. Sarcomere protein dysfunction:

• • Mutations in TTN, MYH7, TNNT2, and ACTC1 disrupt force generation.
• • Leads to impaired cardiomyocyte contraction and compensatory hypertrophy.

2. Nuclear envelope and mechanotransduction:

• • LMNA mutations cause nuclear fragility and altered mechanosignaling.
• • Activates stress pathways (e.g., MAPK/ERK) and promotes apoptosis.

3. Calcium handling and excitation-contraction coupling:

• • Mutations in PLN, RYR2, and CASQ2 alter calcium homeostasis.
• • Results in arrhythmias and contractile dysfunction.

4. Neurohormonal and inflammatory signaling:

• • Chronic activation of beta-adrenergic and renin-angiotensin-aldosterone systems.
• • Contributes to adverse remodeling and fibrosis.

Data sources: ClinVar (2023), gnomAD v2.1.1, DCM Precision Medicine Consortium (2020).

Key signaling networks in DCM pathogenesis include:

• • Beta-adrenergic signaling:
• • Chronic activation leads to cardiomyocyte apoptosis and fibrosis.
• • Downregulation of beta-1 receptors.
• • Calcium/calmodulin-dependent kinase II (CaMKII):
• • Hyperactivation promotes arrhythmias and heart failure.
• • Phosphorylates RyR2 and PLN.
• • MAPK/ERK pathway:
• • Activated by mechanical stress and neurohormonal stimuli.
• • Drives hypertrophic gene program.
• • PI3K/AKT/mTOR pathway:
• • Regulates cell survival and metabolism.
• • Dysregulation contributes to metabolic remodeling.
• • TGF-beta/SMAD signaling:
• • Promotes cardiac fibrosis.
• • Upregulated in response to injury.

Organoid advantages: Cardiac organoids derived from patient iPSCs recapitulate 3D tissue architecture, sarcomere organization, and contractile function. They enable disease modeling and drug screening with patient-specific genetic backgrounds.

Animal models of DCM include:

• • Genetically engineered mouse models (GEMMs):
• • Ttn knockout (haploinsufficient) mice develop DCM.
• • Lmna H222P knock-in mice show nuclear envelope defects.
• • Myh7 R403Q knock-in mice exhibit hypertrophic then dilated phenotype.
• • Induced models:
• • Doxorubicin-induced cardiomyopathy in rodents.
• • Isoproterenol infusion to induce heart failure.
• • Zebrafish models:
• • Ttn truncation mutants show sarcomere disassembly.
• • Useful for high-throughput drug screening.

CRISPR-Cas9 gene editing enables the creation of isogenic cell lines that differ only by a specific mutation, providing clean backgrounds for mechanistic studies. Examples include:

• • TTN knockout in human iPSC-derived cardiomyocytes: Models haploinsufficiency and sarcomere disorganization.
• • LMNA H222P knock-in in HEK293 or iPSCs: Recapitulates nuclear envelope defects and apoptosis.
• • MYH7 R403Q knock-in in cardiomyocytes: Mimics familial DCM with contractile dysfunction.
• • PLN R14del knockout/knock-in: Studies calcium mishandling.

Commercially available, sequence-verified gene-edited cell models accelerate research by eliminating the need for in-house editing and validation. These models are quality-controlled for off-target effects and genomic stability.

Gene-edited cell lines allow functional validation of genetic variants identified in DCM patients. For example:

• • TTN truncating variants: Knockout of TTN in iPSC-derived cardiomyocytes confirms haploinsufficiency and impaired sarcomere assembly.
• • LMNA mutations: Isogenic knock-in lines show nuclear blebbing and increased apoptosis under mechanical stress.
• • CRISPR screens: Genome-wide knockout screens in cardiomyocytes identify modifiers of DCM phenotypes, such as genes in the ubiquitin-proteasome system.

Isogenic pairs (wild-type vs. mutant) enable high-throughput screening of compounds that rescue mutant phenotypes. Applications include:

• • Testing of small molecules that improve contractility in TTN knockout cardiomyocytes.
• • Screening for drugs that prevent LMNA-induced nuclear damage.
• • Modeling resistance to standard heart failure therapies (e.g., beta-blockers) by introducing secondary mutations.

CRISPR synthetic lethality screens in DCM models can identify genetic dependencies and potential biomarkers. For example:

• • Knockout of TTN in combination with other sarcomere genes reveals synthetic lethal interactions.
• • Transcriptomic profiling of isogenic lines identifies differentially expressed genes as candidate biomarkers.
• • Proteomic analysis of secreted factors from mutant cardiomyocytes uncovers circulating biomarkers for early detection.